Modelling the cost effectiveness of interventions for osteoporosis: issues to consider.
Expenditure on treating osteoporotic fractures and on preventative intervention is considerable and is likely to rise in forthcoming years due to the association between fracture risk and age. With funders such as the National Institute for Health and Care Excellence and the Pharmaceutical Benefits Advisory Committee explicitly considering cost-effectiveness analyses within the process of producing guidance, it is imperative that economic models are as robust as possible. This article details issues that need to be considered specifically related to health technology assessments of interventions for osteoporosis, and highlights limitations within the current evidence base. A likely direction of impact on cost effectiveness of addressing the key issues has been included alongside a tentative categorization of the level of these impacts. It is likely that cost-effectiveness ratios presented in previous models that did not address the identified issues were favourable to interventions.
University of Sheffield, School of Health and Related Research, 30 Regent Street, Sheffield, S1 4DA, UK, m.d.stevenson@sheffield.ac.uk.
Matt D
MD
Stevenson
Peter L
PL
Selby
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D050723:Fractures, Bone / Q000191:economics / Q000517:prevention & control*; D006801:Humans; D018803:Models, Economic; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D017410:Practice Guidelines as Topic; D013673:Technology Assessment, Biomedical / Q000191:economics*; D006113:United Kingdom
D050071:Bone Density Conservation Agents